| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Transforming growth factor beta-3;TGF-beta-3;Latency-associated peptide;LAP;TGFB3; |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Expression System | |
| Gene ID | |
| Immunogen | Expression system for standard: NS0; Immunogen sequence: A301-S412 |
| Product Type | |
| Reactivity | |
| Sample Type(s) | cell culture supernatants, serum, plasma (EDTA) and urine. |
| Sensitivity | |
| Storage | |
| Target | |
| UniProt # |
Background
Also known as: Transforming growth factor beta-3, TGF-beta-3, Latency-associated peptide, LAP, TGFB3.
Human TGF-Beta 3 (TGFB3) is a commonly measured biological analyte that can provide insight into cellular state and tissue physiology. This target is frequently investigated in Molecular & Cellular Biology research contexts. Growth factors and morphogens regulate cell proliferation, differentiation, survival, and tissue remodeling by engaging surface receptors and activating downstream signaling cascades. Their activity is often context-dependent, shaped by receptor availability, extracellular matrix binding, and feedback regulation.
Biological function and mechanism
In many systems, growth-factor signaling integrates environmental cues with developmental or repair programs. Downstream pathways frequently include kinase signaling modules and transcriptional responses that alter cell-cycle control, migration, or lineage specification. Because these signals can be transient, quantitative measurements are useful for understanding timing and dose dependence.
Why it matters in research
- Pathway engagement: Concentration changes can indicate activation of growth, survival, or differentiation programs.
- Tissue remodeling: Levels may relate to repair, fibrosis, angiogenesis, or developmental patterning in model systems.
- Mechanistic studies: Tracking abundance alongside downstream markers helps connect ligand availability to signaling output.
Disease and translational relevance
Altered growth-factor signaling has been reported across diverse conditions, including cancer biology, cardiovascular remodeling, wound repair, and metabolic dysfunction. For research interpretation, consider whether the measured form represents active ligand, bound complexes, or processed fragments, as these can influence apparent levels.
Sample data
| Concentration (pg/ml) | 0 | 31.2 | 62.5 | 125 | 250 | 500 | 1000 | 2000 |
| O.D. | 0.007 | 0.087 | 0.143 | 0.236 | 0.438 | 0.783 | 1.365 | 2.206 |
Intra/inter assay consistency
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 16 | 16 | 16 | 24 | 24 | 24 |
| Mean (pg/ml) | 66 | 244 | 776 | 70 | 242 | 733 |
| Standard deviation | 2.83 | 13.17 | 35.49 | 3.71 | 14.27 | 42.51 |
| CV (%) | 4.3% | 5.4% | 4.6% | 5.3% | 5.9% | 5.8% |
Kit components
Description|Quantity Pre-coated 96-well strip microplate|1 Standard|2 vials Biotinylated antibody (100x)|100ul Avidin-Biotin-Peroxidase Complex (100x)|100ul Sample Diluent|30ml Antibody Diluent|12ml Avidin-Biotin-Peroxidase Diluent|12ml Color Developing Reagent (TMB)|10ml Stop Solution|10ml Wash Buffer (25x)|20ml Adhesive plate sealers|4Materials required but not provided
- Microplate Reader capable of reading absorbance at 450nm.
- Incubator.
- Automated plate washer (optional).
- Pipettes and pipette tips capable of precisely dispensing 0.5 µl through 1 ml volumes of aqueous solutions.
- Multichannel pipettes are recommended for large amount of samples.
- Deionized or distilled water.
- 500ml graduated cylinders.
- Test tubes for dilution.
Activating reagent preparation
TGF beta 3 is mostly contained as inactive form in samples, please activate it before assay. Don't activate recombinant TGF beta 3.
Solution A: 1N HCI: add 8.33ml of 12N HCI into 91.67ml of H2O.
Solution B: 1.2N NaOH/0.5M HEPES: add 12ml of 10N NaOH and 11.9g HEPES into 75ml of H2O, add H2O to adjust volume to 100ml.
Sample activation procedure
Activate the sample
Cell culture supernatants, urine: add activating reagent pro rata, i.e. add 20μl of Solution A into 100μl of sample, 10 min later, add 20μl of Solution B. PH 7.0-7.6.
Serum, plasma(EDTA): add activating reagent pro rata, i.e. add 20μl of Solution A into 40μl of sample, 10 min later, add 20μl of Solution B. PH 7.0-7.6.
It is unnecessary to activate the recombinant TGF-beta 3.
Sample was diluted partly after adding activating reagent, so please pay attention to this when calculate target protein concentration.
►How many samples can I run per plate?
►What sample dilution should I use?
►Why is my signal weak or absent?
►Why is my background signal high?
►Are the kit components sterile?
►How do I analyze my ELISA results?
►How should I store samples before running the assay?
►What positive and negative controls should I include?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Chang et al. (2025). Bufalin inhibits immune escape in metastatic colorectal cancer by regulating M2 macrophage polarization. APOPTOSIS.
- He et al. (2025). Magnetic Nanoactuator-Protein Fiber Coated Hydrogel Dressing for Well-Balanced Skin Wound Healing and Tissue Regeneratio…. ACS Nano.
- Wang et al. (2024). Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-β and SMAD3 signali…. JOURNAL OF AUTOIMMUNITY.
- Donghao et al. (2024). Mechanism of bufalin inhibition of colon cancer liver metastasis by regulating M2-type polarization of Kupffer cells ind…. APOPTOSIS.
- Yu et al. (2023). A pilot study of S100A4, S100A8/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis?. ESC Heart Failure.
- Zhang et al. (2023). METTL3-mediated HPV vaccine enhances the effect of anti PD-1 immunotherapy to alleviate the development of cutaneous squ…. ANAIS BRASILEIROS DE DERMATOLOGIA.
- Dayasagar et al. (2023). Dominance and improved survivability of human γδT17 cell subset aggravates the immunopathogenesis of pemphigus vulgaris. IMMUNOLOGIC RESEARCH.
- Wang et al. (2023). Circulating Tfr/Tfh cell imbalance may contribute to the immunopathogenesis of pemphigus. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.
- Chuang et al. (2023). Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
- Cui et al. (2023). Injectable and Degradable POSS–Polyphosphate–Polysaccharide Hybrid Hydrogel Scaffold for Cartilage Regeneration. ACS Applied Materials & Interfaces.
- Özdoğan et al. (2020). Development and in vitro evaluation of gel formulation of atorvastatin solid dispersions. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY.
- Sonali et al. (2019). Transient Mitomycin C-treatment of human corneal epithelial cells and fibroblasts alters cell migration, cytokine secret…. Scientific Reports.
- Özdoğan et al. (2018). Development and in vitro evaluation of chitosan based system for local delivery of atorvastatin for treatment of periodo…. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES.
- Yang et al. (2025). TREM2-mediated neuroinflammatory response is involved in AgNPs-induced ferroptosis in HMC3 cells. NEUROTOXICOLOGY.
- (2025). TREM2-mediated neuroinflammatory response is involved in AgNPs-induced ferroptosis in HMC3 cells.